A vaccine that stops nicotine from producing pleasurable feelings is moving into Phase I trials in the Netherlands.
When it crosses the blood-brain barrier, nicotine stimulates the production of neurotransmitters responsible for emotional highs, making it highly addictive.
The vaccine, NicVAX by US-based Nabi Biopharmaceuticals, is derived from nicotine.
Researchers hope that by injecting it into the bloodstream they can stimulate the immune system to produce antibodies that bind to nicotine and prevent it from crossing the blood-brain barrier. More here.